Calibrant Biosystems announced a inquest collaboration with the Cleveland Clinic to select novel drug targets for primary brain cancer using Calibrant's Gemini proteomics platform. As part of the partnership, Calibrant will distinguish protein neural expert systems and novel therapeutic targets involved in the progression of the most common and aggressive primary brain cancer, glioblastoma multiforme (GBM).

More: - Brought to my attention by